A quick update on Apoptone in hormone-refractory prostate cancer

Posted on June 12, 2010 by Sitemaster

Back in 2008 we first mentioned the initiation of clinical trials of a drug called Apoptone or HE3235 in men with hormone-refractory prostate cancer. Data on the development of Apoptone was another item on the agenda at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this week. … READ MORE …

Filed under: Drugs in development, Uncategorized | Tagged: , , , | Leave a comment »

The Tuesday news report: January 27, 2009

Posted on January 27, 2009 by Sitemaster

Today’s news deals with such items as:

  • Toxicities associated with hypofractionated, intensity-modulated radiation therapy
  • Incidental prostate cancer in male patients undergoing radical cystoprostatectomy for treatment of bladder cancer
  • A Spanish review of photodynamic therapy
  • A proposed mechanism of action for the investigational drug Apoptone™ (HE3235) … READ MORE …

Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: , , , , , | Leave a comment »

The prostate cancer news for Thursday, July 30

Posted on July 31, 2008 by Sitemaster

News items today are focused on information about:

  • a new way of approaching treatment of hormone-refractory disease
  • the initial clinical trials of a new drug candidate in hormone-refractory patients
  • the association between hospital and surgeon volume and patient outcomes after radical prostatectomy. … MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , , , , , , | Leave a comment »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives